Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A.
Tranholm M, Kristensen K, Kristensen AT, Pyke C, Rojkjaer R, Persson E
Blood 2003;102(10):3615-3620.
Review by
NovoSeven: mode of action and use in acquired haemophilia.
Von Depka M
Intensive Care Med 2002;28(Suppl 2):S222-S227.
Review by M. Aldouri
Continuous infusion of coagulation factor products.
Stachnik JM, Gabay MP
Ann Pharmacother 2002;36(5):882-891.
Review by
Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage.
Gerotziafas GT, Zervas C, Gavrielidis G, et al.
Am J Hematol 2002;69(3):219-222.
Review by M. Aldouri
Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high responding inhibitors.
O’Connell N, McMahon C, Smith J, et al.
Br J Haematol 2002;116(3):632-635.
Review by Aldouri M
Successful use of recombinant activated factor VII for trauma-associated hemorrhage in a patient without preexisting coagulopathy.
O’Neill PA, Bluth M, Gloster ES, et al.
J Trauma 2002;52(2):400-405.
Review by Aldouri M
Successful use of recombinant factor VIIa for hemostasis during total knee replacement in a severe hemophiliac with high-titer factor VIII inhibitor.
Carr ME, Loughran TP, Cardea JA, Smith WK, Kuhn JG, Dottore MV
Int J Hematol 2002;75(1):95-99.
Review by
Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures.
Cooper HA, Jones CP, Campion E, Roberts HR, Hedner U
Haemophilia 2001;7(5):517-522.
Review by M. Aldouri